Education
About Us
Working with TipRanks
Follow Us
Beyond Air Inc (XAIR)
NASDAQ:XAIR
XAIR Stock Chart & Stats
$1.27
-$0.04(-9.27%)
At close: 4:00 PM EST
$1.27
-$0.04(-9.27%)
Day’s Range― - ―
52-Week Range$0.67 - $10.41
Previous CloseN/A
Volume845.14K
Average Volume (3M)6.04M
Market Cap
$10.17M
Enterprise Value$8.33M
Total Cash (Recent Filing)$10.70M
Total Debt (Recent Filing)$11.80M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Feb 13, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding8,009,488
10 Day Avg. Volume277,876
30 Day Avg. Volume6,042,452
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.36
Price to Sales (P/S)4.98
P/FCF Ratio-0.42
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit-21.42
Enterprise Value/Ebitda-0.26
Forecast
1Y Price Target
$5.50Price Target Upside333.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset MonetizationSale of a majority stake in the NeuroNOS subsidiary to XTL delivered upfront cash, retained equity and milestone-based payments that bolster the balance sheet without issuing new shares.
Financial FlexibilitySecuring a debt facility and access to an equity line, combined with a year-over-year reduction in net cash burn, extends financial runway and supports continued commercialization and development efforts.
Regulatory Label ExpansionA potential FDA decision on a supplemental application to expand LungFit PH's label to include certain cardiac surgeries could meaningfully broaden the device's addressable market and increase hospital adoption.
Bears Say
Commercial Leadership DisruptionLowered revenue guidance tied to commercial leadership changes raises concerns about sales execution and the speed of market recovery.
Guidance RevisionRevised fiscal 2026 guidance was lowered, reducing revenue expectations and signaling difficulty in meeting earlier growth forecasts.
Quarterly Revenue ShortfallSecond-quarter 2026 revenue missed consensus and internal estimates, pointing to short-term weakness in commercial performance.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $0.67 and its highest was $10.41 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $10.17M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Feb 13, 2026 which is in 14 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Nov 10, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$0.773 by -$0.477.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Undervalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -0.75.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 8,009,488 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$1.25 in its last earnings report, missing expectations of -$0.773. Following the earnings report the stock price went down -16.092%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
XAIR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, global expansion, and financial stability, though these were offset by leadership transitions and flat sequential revenue growth.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
$5.50
▲(333.07% Upside)
Technical Analysis
Pulmonx
―
Hyperfine
―
TriSalus Life Sciences
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Ownership Overview
Currently, No data available
---